Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?

Tan, Seng Kiong; Cooper, Mark E.

doi:10.1080/14728214.2023.2277762

Cited by 1 publication

(1 citation statement)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies in animal models showed that deficiency of glucagon receptors in nephron tubules leads to inflammatory damage, fibrosis, water, and electrolyte imbalances [102]. On the contrary, an activation of glucagon receptors may reduce perirenal adiposity, improve renal blood flow and glomerular filtration, and may indirectly influence solute transport in the proximal renal tubules [103]. Finally, further evidence might emerge on the role of glucagon receptors activation from a phase IIb double-blind trial with retatrutide, a new triple agonist of GIP, GLP-1, and glucagon receptors [104].…”

Section: Glucagon-like Peptide-1 Receptor Agonistsmentioning

confidence: 99%

Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection

Mazzieri,

Porcellati,

Timio

et al. 2024

IJMS

View full text Add to dashboard Cite

Diabetic kidney disease (DKD) is a chronic microvascular complication in patients with diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD). Although glomerulosclerosis, tubular injury and interstitial fibrosis are typical damages of DKD, the interplay of different processes (metabolic factors, oxidative stress, inflammatory pathway, fibrotic signaling, and hemodynamic mechanisms) appears to drive the onset and progression of DKD. A growing understanding of the pathogenetic mechanisms, and the development of new therapeutics, is opening the way for a new era of nephroprotection based on precision-medicine approaches. This review summarizes the therapeutic options linked to specific molecular mechanisms of DKD, including renin-angiotensin-aldosterone system blockers, SGLT2 inhibitors, mineralocorticoid receptor antagonists, glucagon-like peptide-1 receptor agonists, endothelin receptor antagonists, and aldosterone synthase inhibitors. In a new era of nephroprotection, these drugs, as pillars of personalized medicine, can improve renal outcomes and enhance the quality of life for individuals with DKD.

show abstract

Section: Glucagon-like Peptide-1 Receptor Agonistsmentioning

confidence: 99%